Login to Your Account



Addex, Merck Ink $702M Deal for Schizophrenia Compound

By Cormac Sheridan


Wednesday, January 9, 2008
Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription